The Usher Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Usher Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Usher Syndrome. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued products.

GlobalData tracks 24 drugs in development for Usher Syndrome by 18 companies/universities/institutes. The top development phase for Usher Syndrome is preclinical with 15 drugs in that stage. The Usher Syndrome pipeline has 19 drugs in development by companies and five by universities/ institutes. Some of the companies in the Usher Syndrome pipeline products market are: Odylia Therapeutics, Case Western Reserve University and ProQR Therapeutics.

The key targets in the Usher Syndrome pipeline products market include Usherin (Usher Syndrome Type 2A Protein or USH2A), Clarin 1 (Usher Syndrome Type 3 Protein or CLRN1), and Harmonin (Antigen NY-CO-38/NY-CO-37 or Autoimmune Enteropathy Related Antigen AIE75 or Protein PDZ73 or Renal Carcinoma Antigen NY-REN-3 or Usher Syndrome Type 1C Protein or USH1C).

The key mechanisms of action in the Usher Syndrome pipeline product include Usherin (Usher Syndrome Type 2A Protein or USH2A) Activator with nine drugs in Preclinical. The Usher Syndrome pipeline products include three routes of administration with the top ROA being Intravitreal and four key molecule types in the Usher Syndrome pipeline products market including Gene Therapy, and Antisense Oligonucleotide.

Usher Syndrome overview

Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration; prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids, and Vitamin A supplementation.

For a complete picture of Usher Syndrome’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.